Abstract:Control of xenograft rejection in experimental models has been a challenge. The direct targeting of T cells enabled allotransplantation, but this approach has been less effective in xenotransplantation. Various genetic modifications like α-1,3 galactosyltransferase gene-knockout, transgenic expression of human complement regulatory proteins (CD46), and coagulation-regulatory protein thrombomodulin have been the key to avoiding early cardiac xenograft rejection. The potential of the CRISPR technique 1 , 2 in addition to an improved immunosuppression regimen including costimulation blockade, for example, anti-CD154mAb and anti-CD40mAb, plus elimination of the B-cell response have advanced the field. 3 , 4 With these manipulations, nonlife supporting, heterotopic cardiac xenograft survival has been extended to 945 days. 5 , 6 In their recent letter to Nature, Längin et al 7 report early, consistent survival in an experimental orthotopic cardiac xenotransplantation model. Those results demonstrate yet another milestone in moving the xenotransplant closer to a clinical application. The data by the Munich group can be considered a game changer as the authors have successfully translated the recently reported significant cardiac xenograft survival in a heterotopic position 5 to an orthotopic transplant model and have demonstrated the required life-sustaining capability of a genetically engineered pig hearts transplanted into baboon. It is not clear what regulatory agencies will consider sufficient to move forward with clinical xenotransplantation. The International Society for Heart and Lung Transplantation suggests that success in a large animal model will include 60% graft survival for a follow-up of 3 months and 50% survival in a 6 months' observation. 8 The study by Längin et al 7 included 12 transplants, with 2 baboons surviving 90 days and 2 animals surviving beyond 6 months. The first 2 transplants were electively terminated due to restriction of only 90-day survival by their study protocol. The authors then received permission to extend the survival for 6 months, and the latter 2 transplants were therefore electively terminated after crossing 6-month survival (182 and 195 days, respectively). 7 A few key findings of this study should be emphasized. According to the authors, the use of cold (−8°C) nonischemic continuous perfusion of the donor's heart in a special chamber with Steen solution 9 containing red blood cells (15% hematocrit) for 3 hours before implant appeared beneficial. Maintenance immunosuppression included anti-inflammatory drugs targeting interleukin (IL)-6, IL-1, and tumor necrosis factor (TNF)-α. Treatment also included temsirolimus, a prodrug of rapamycin and a specific inhibitor of the phosphatidylinositol 3-protein kinase (mTOR) family that inhibits cell cycle progression. The authors demonstrated in the 2 longest-term survivors that the withdrawal of temsirolimus led to hypertrophy and physiological overgrowth of the naturally aging porcine heart in the baboon. It is unclear if temsirolimus application had been essential as directly inhibiting xenograft hypertrophy or as an immunosuppressant. Potential side effects of extended use of temsirolimus are not discussed, and it is not known whether the withdrawal of this drug was elective or due to complications. A continuous intravenous infusion of antihypertensive drugs, enalapril and metoprolol, was implemented to achieve "porcine-like" hemodynamics, with a target systolic pressure of 80 mm Hg and heart rate of 100, in an effort to further mitigate xenograft overgrowth. Controlling hemodynamic changes alone appeared insufficient to prevent xenograft overgrowth, as the addition of temsirolimus seemed necessary, suggesting that intrinsic factors beyond hemodynamic control contribute to the porcine heart. While the overall clinical success is significant, it remains difficult to tease out which of the individual therapeutics have been necessary. The mechanism by which nonischemic continuous organ perfusion is superior compared to conventional cold preservation techniques for myocardial preservation is unclear. The authors used the Steen solution 9 that has traditionally been used for lung preservation with a composition that differs from conventional crystalloid cardioplegia. Moreover, detailed mechanisms on how appropriate xenograft size is maintained remain unclear. If growth restriction is necessary, use of minipigs or growth hormone receptor-deficient pigs could hel -Abstract Truncated-

Continuous Immunosuppression is Required for Suppressing Immune Responses to Xenografts in Non-Human Primate Brains

Hypoproliferative human neural progenitor cell xenografts survived extendedly in the brain of immunocompetent rats

Abstract 2620: Differential Effects of Cyclosporine Regimens on Rat Brain Responses to Human Neural Cell Grafts

Immune Suppression Produced by Intrathymic Inoculation with Xenogeneic Antigen and Whole-Body Γ-Irradiation in a Pig-to-monkey Heart Transplantation Model.

The Long-Term Survival and Functional Maturation of Human Inpc-Derived Neurons in the Basal Forebrain of Cynomolgus Monkeys

Xenotransplantation: A Step Closer to Clinical Reality?

In Vivo Ontogeny of Human Forebrain Neural Progenitor Cell Grafts in Adult Rats: an Immunohistological Study

Transplant Tolerance: Current Insights and Strategies for Long-Term Survival of Xenografts

Tolerance in a concordant nonhuman primate model

An Immunotherapeutic Strategy for Prolonging Graft Survival in Mice.

Lack of Remuscularization Following Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitor Cells in Infarcted Nonhuman Primates

Control of the Survival and Growth of Human Glioblastoma Grafted Into the Spinal Cord of Mice by Taking Advantage of Immunorejection

The Immunobiology of Pig-to-nonhuman Primate Islet Xenotransplantation: Insights, Innovation, and Impact

Intracerebral xenotransplantation of GFP mouse bone marrow stromal cells in intact and stroke rat brain: graft survival and immunologic response

Ex vivo-expanded baboon CD39 + regulatory T cells prevent rejection of porcine islet xenografts in NOD-SCID IL-2rγ-/- mice reconstituted with baboon peripheral blood mononuclear cells

Trophic and immunoregulatory properties of neural precursor cells: benefit for intracerebral transplantation

Therapeutic regulation of systemic inflammation in xenograft recipients

Characterization of Human-Induced Neural Stem Cells and Derivatives following Transplantation into the Central Nervous System of a Nonhuman Primate and Rats

Xenoantigen Deletion and Chemical Immunosuppression Can Prolong Renal Xenograft Survival

[Immune Reconstitution in Immunosuppressed Pigs with Human Immune Competent Cells].

Induction of immunological tolerance to myelinogenic glial-restricted progenitor allografts